Smidt Heart Institute, Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Precision Biomarker Laboratories, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Clin Chem. 2022 Mar 4;68(3):450-460. doi: 10.1093/clinchem/hvab202.
Accurate discovery assay workflows are critical for identifying authentic circulating protein biomarkers in diverse blood matrices. Maximizing the commonalities in the proteomic workflows between different biofluids simplifies the approach and increases the likelihood for reproducibility. We developed a workflow that can accommodate 3 blood-based proteomes: naive plasma, depleted plasma and dried blood.
Optimal conditions for sample preparation and data independent acquisition-mass spectrometry analysis were established in plasma then automated for depleted plasma and dried blood. The mass spectrometry workflow was modified to facilitate sensitive high-throughput analysis or deeper profiling with mid-throughput analysis. Analytical performance was evaluated by the linear response of peptides and proteins to a 6- or 7-point dilution curve and the reproducibility of the relative peptide and protein intensity for 5 digestion replicates per day on 3 different days for each biofluid.
Using the high-throughput workflow, 74% (plasma), 93% (depleted), and 87% (dried blood) displayed an inter-day CV <30%. The mid-throughput workflow had 67% (plasma), 90% (depleted), and 78% (dried blood) of peptides display an inter-day CV <30%. Lower limits of detection and quantification were determined for peptides and proteins observed in each biofluid and workflow. Based on each protein and peptide's analytical performance, we could describe the observable, reliable, reproducible, and quantifiable proteomes for each biofluid and workflow.
The standardized workflows established here allows for reproducible and quantifiable detection of proteins covering a broad dynamic range. We envisage that implementation of this standard workflow should simplify discovery approaches and facilitate the translation of candidate markers into clinical use.
准确的发现分析工作流程对于在不同的血液基质中鉴定真实的循环蛋白生物标志物至关重要。最大限度地提高不同生物流体之间蛋白质组学工作流程的共性可以简化方法并增加可重复性。我们开发了一种适用于三种基于血液的蛋白质组学的工作流程:原始血浆、耗尽血浆和干血斑。
在血浆中建立了样品制备和数据独立采集-质谱分析的最佳条件,然后对耗尽血浆和干血斑进行了自动化处理。修改了质谱工作流程,以促进敏感的高通量分析或使用中通量分析进行更深层次的分析。通过对每个生物流体的 3 天内每天 5 次消化重复的 6 或 7 点稀释曲线的肽和蛋白质的线性响应以及相对肽和蛋白质强度的重复性来评估分析性能。
使用高通量工作流程,74%(血浆)、93%(耗尽)和 87%(干血斑)显示日内 CV<30%。中通量工作流程中,67%(血浆)、90%(耗尽)和 78%(干血斑)的肽显示日内 CV<30%。确定了每种生物流体和工作流程中观察到的肽和蛋白质的检测限和定量限。基于每个蛋白质和肽的分析性能,我们可以描述每种生物流体和工作流程的可观察、可靠、可重复和可定量的蛋白质组。
这里建立的标准化工作流程允许对涵盖广泛动态范围的蛋白质进行可重复和定量检测。我们设想,实施这种标准工作流程应该简化发现方法,并促进候选标志物向临床应用的转化。